A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection

Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejection therapy between 2012 and 2022 in our institution...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vugt, Lukas K., van der Zwan, Marieke, Clahsen-van Groningen, Marian C., van Agteren, Madelon, Hullegie-Peelen, Daphne M., De Winter, Brenda C. M., Reinders, Marlies E. J., Miranda Afonso, Pedro, Hesselink, Dennis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660975/
https://www.ncbi.nlm.nih.gov/pubmed/38020744
http://dx.doi.org/10.3389/ti.2023.11834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660975/
https://www.ncbi.nlm.nih.gov/pubmed/38020744
http://dx.doi.org/10.3389/ti.2023.11834

Ejemplares similares